All In Biotech

Drug Trial Radar · NCT06816992

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Phase 1b Study of ORIC-114 in Combination With Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

76

Planned (sponsor's estimate)

Start

Feb 27, 2025

Primary completion

Dec 2026

Study completion Dec 2027

Sponsor

Lead sponsor
ORIC PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Janssen Research & Development, LLC
First posted
Feb 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with subcutaneous (SC) amivantamab in patients with advanced or metastatic NSCLC harboring an EGFR exon 20 insertion mutation.

Conditions

  • Solid Tumors
  • EGFR Exon 20 Insertion Mutations
  • NSCLC
  • EGFR-mutated NSCLC

Interventions

  • ORIC-114 Dose 1 + amivantamabDrug

    ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection

  • ORIC-114 Dose 2 + amivantamabDrug

    ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection

  • ORIC-114 Dose 3 + amivantamabDrug

    ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase 2 Dose (RP2D)Time frame: 12 months
  2. Objective response rate (ORR)Time frame: 12 months
  3. Duration of response (DOR)Time frame: 12 months
  4. Progression-free survival (PFS)Time frame: 12 months

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • NYU Langone Health

    New York, New York · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Not yet recruiting

  • The Princess Margaret Hospital

    Toronto, Ontario, Canada · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.